Type II CRISPR/Cas9 approach in the oncological therapy

por Biagioni, A., Chillà, A., Andreucci, E., Laurenzana, A., Margheri, F., Peppicelli, S., Del Rosso, M., Fibbi, G.
Publicado 2017

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086

por Cellai, C, Laurenzana, A, Vannucchi, A M, Caporale, R, Paglierani, M, Di Lollo, S, Pancrazzi, A, Paoletti, F
Publicado 2006

The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells

por Cellai, C, Balliu, M, Laurenzana, A, Guandalini, L, Matucci, R, Miniati, D, Torre, E, Nebbioso, A, Carafa, V, Altucci, L, Romanelli, M N, Paoletti, F
Publicado 2012

u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression

por Ciavarella, S, Laurenzana, A, De Summa, S, Pilato, B, Chillà, A, Lacalamita, R, Minoia, C, Margheri, F, Iacobazzi, A, Rana, A, Merchionne, F, Fibbi, G, Del Rosso, M, Guarini, A, Tommasi, S, Serratì, S
Publicado 2017